Cargando…

Secondary cytoreduction surgery improves prognosis in platinum-sensitive recurrent ovarian cancer

BACKGROUND: There is no consensus regarding the secondary cytoreduction surgery (CRS) in recurrent ovarian cancer patients. The present study aims to determine the value of secondary CRS and the eligible subgroup for this procedure. METHODS: 96 platinum-sensitive recurrent ovarian cancer patients we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Xia, Chen, Xiaoxiang, Dai, Zhiqin, Deng, Fei, Qu, Junwei, Ni, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3847054/ https://www.ncbi.nlm.nih.gov/pubmed/24059600 http://dx.doi.org/10.1186/1756-9966-32-61

Ejemplares similares

Update on the secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: a narrative review
por: Conte, Carmine, et al.
Publicado: (2021)

The role of secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer: what do the trials tell us?
por: Coleman, Robert L.
Publicado: (2020)

Phase 2 non-randomised trial of secondary cytoreduction and hyperthermic intraperitoneal chemotherapy in recurrent platinum-sensitive ovarian cancer
por: Raj, Hemanth, et al.
Publicado: (2021)

Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancer
por: Zou, Ruoyao, et al.
Publicado: (2023)

The current role of secondary cytoreductive surgery for recurrent ovarian cancer
por: de Bree, Eelco, et al.
Publicado: (2022)

A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study
por: Shi, Tingyan, et al.
Publicado: (2020)

The value of secondary neoadjuvant chemotherapy in platinum-sensitive recurrent ovarian cancer: a case-control study post GOG-0213 trial
por: Gu, Hongyuan, et al.
Publicado: (2020)

Simplified Selection Criteria for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer
por: Son, Joo-Hyuk, et al.
Publicado: (2022)

Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study
por: Petrillo, Marco, et al.
Publicado: (2019)

Addendum: A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study
por: Shi, Tingyan, et al.
Publicado: (2022)

Artificial intelligence weights the importance of factors predicting complete cytoreduction at secondary cytoreductive surgery for recurrent ovarian cancer
por: Bogani, Giorgio, et al.
Publicado: (2018)

Comments on: Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study
por: Batista, Thales Paulo, et al.
Publicado: (2019)

Minimally-Invasive Secondary Cytoreduction in Recurrent Ovarian Cancer
por: Certelli, Camilla, et al.
Publicado: (2023)

Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection
por: Onda, T, et al.
Publicado: (2005)

Which patients benefit from secondary cytoreductive surgery in recurrent ovarian cancer?
por: Zang, Rongyu, et al.
Publicado: (2019)

Prediction Models for Complete Resection in Secondary Cytoreductive Surgery of Patients With Recurrent Ovarian Cancer
por: Jiang, Caixia, et al.
Publicado: (2021)

Role of HIPEC after Complete Cytoreductive Surgery (CRS) in Peritoneal Recurrence of Platinum-Sensitive Recurrent Ovarian Cancer (OC): The Aim for Standardization at Two Reference Centers for CRS
por: Acs, Miklos, et al.
Publicado: (2023)

Cytoreductive Surgery (CRS) Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Platinum-Sensitive Recurrence Epithelial Ovarian Cancer With HRR Mutation: A Phase III Randomized Clinical Trial
por: Qi, Yuwen, et al.
Publicado: (2022)

CA-125–indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery
por: Wang, Fang, et al.
Publicado: (2013)

Investigating the effect of optimal cytoreduction in the context of platinum sensitivity in high‐grade serous ovarian cancer
por: Cardillo, Nicholas, et al.
Publicado: (2022)

Platinum resistant recurrence and early recurrence in a multi-centre cohort of patients undergoing interval cytoreductive surgery for advanced epithelial ovarian cancer
por: Bhatt, Aditi, et al.
Publicado: (2022)

A score system for complete cytoreduction in selected recurrent ovarian cancer patients undergoing secondary cytoreductive surgery: predictors- and nomogram-based analyses
por: Bogani, Giorgio, et al.
Publicado: (2018)

Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer
por: Jeong, Soo Young, et al.
Publicado: (2019)

Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study
por: van de Laar, Rafli, et al.
Publicado: (2014)

Ovarian Carcinosarcoma: Effects of Cytoreductive Status and Platinum-Based Chemotherapy on Survival
por: Jernigan, Amelia M., et al.
Publicado: (2013)

Cytoreductive surgery in ovarian cancer
por: Pomel, Christophe, et al.
Publicado: (2007)

The value of PET/CT for cytoreductive surgery selection in recurrent ovarian carcinoma
por: Nunes, Rafael Leite, et al.
Publicado: (2023)

The efficacy of secondary cytoreductive surgery for recurrent ovarian, tubal, or peritoneal cancer in Tian-model low-risk patients
por: So, Makiko, et al.
Publicado: (2019)

Laparoscopic splenectomy both for primary cytoreductive surgery for advanced ovarian cancer and for secondary surgery for isolated spleen recurrence: feasibility and technique
por: Macciò, Antonio, et al.
Publicado: (2021)

Successful secondary radical operation on unretractable metastatic platinum-sensitive recurrent ovarian cancer by immunotherapy: a case report
por: Sun, Li, et al.
Publicado: (2022)

Effect of BRCA1/2 Mutational Status on Survival Outcomes According to Secondary Cytoreductive Surgery and Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer: A Real-World Evidence Study
por: Kim, Se Ik, et al.
Publicado: (2023)

Surgery in platinum-resistant recurrent epithelial ovarian carcinoma
por: Zhao, Ling-Qin, et al.
Publicado: (2022)

Successful treatment of platinum refractory ovarian clear cell carcinoma with secondary cytoreductive surgery and implantable transponder placement to facilitate targeted volumetric arc radiation therapy
por: Fehniger, Julia, et al.
Publicado: (2018)

Platinum-Sensitive Recurrence in Ovarian Cancer: The Role of Tumor Microenvironment
por: Chien, Jeremy, et al.
Publicado: (2013)

Maintenance with Trabectedin in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer
por: Guerra Alía, Eva María, et al.
Publicado: (2019)

Tertiary cytoreduction in the setting of recurrent ovarian cancer (Review)
por: DOGAN, NASUH UTKU, et al.
Publicado: (2013)

Cytoreductive Surgery for Heavily Pre-Treated, Platinum-Resistant Epithelial Ovarian Carcinoma: A Two-Center Retrospective Experience
por: Tuninetti, Valentina, et al.
Publicado: (2020)

Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort
por: Zang, R Y, et al.
Publicado: (2011)

Recurrent ovarian cancer with multiple lymph nodes metastases successfully treated with lymphadenectomy as secondary cytoreductive surgery: A case report
por: Nagano, Hiroaki, et al.
Publicado: (2014)

The survival outcome and complication of secondary cytoreductive surgery plus chemotherapy in recurrent ovarian cancer: a systematic review and meta-analysis
por: Ding, Ting, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_khmkjuaqrocfrh4knjlcrjpv0s